Oral semaglutide pills: trials, evidence and safety

Complete guide: GLP-1 drugs: a complete guide to semaglutide and beyond

What is semaglutide in pill form?

Oral semaglutide (also called semaglutide pills or tablets) is the same peptide molecule as the injectable version, a GLP-1 receptor agonist, formulated as a tablet that is swallowed¹⁴. Two presentations are FDA-approved. Rybelsus was approved on 20 September 2019 "to improve control of blood sugar in adult patients with type 2 diabetes", alongside diet and exercise, and was the first oral GLP-1¹. The Wegovy pill (oral semaglutide 25 mg once daily) was approved on 22 December 2025 to reduce excess body weight, maintain the reduction long term and reduce the risk of major adverse cardiovascular events³.

Being a pill does not make it a different molecule or a "natural GLP-1": it is still a derivatized peptide, which is why it needs special help to be absorbed⁴. That is the difference with orforglipron, an oral GLP-1 that is not a peptide, reviewed in Non-peptide oral GLP-1: orforglipron.

How is a peptide absorbed by mouth? The role of SNAC

A large peptide is usually destroyed in the gut and crosses the intestinal wall poorly. For oral semaglutide, the manufacturer combined it in the tablet with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), an absorption enhancer. A study in humans and dogs showed that absorption takes place in the stomach, is confined to the area close to the tablet surface, and does not occur without SNAC; SNAC protects against enzymatic degradation through a local buffering effect and enhances absorption only transiently. The mechanism is transcellular, with no effect on tight junctions⁴.

That physiology explains the label's conditions: the tablet is taken on an empty stomach in the morning with water (up to 4 ounces) and at least 30 minutes must pass before eating, drinking anything else or taking other oral medicines². Absolute bioavailability is only 0.4% to 1%², which is why the oral dose (7 and 14 mg in diabetes, 25 mg in the Wegovy pill) is far higher than that of the weekly pen (2.4 mg)¹⁵.

What is Rybelsus used for? Evidence in type 2 diabetes

Rybelsus is used for glycemic control in adults with type 2 diabetes, as an adjunct to diet and exercise, and the current label (revised January 2026) also lists reducing the risk of major adverse cardiovascular events². The PIONEER program supports the first use:

• PIONEER 1 (703 adults, 26 weeks, diet and exercise only): HbA1c fell 0.6, 0.9 and 1.1 points more than placebo with the 3, 7 and 14 mg arms; weight fell 2.3 kg more with 14 mg⁵.
• PIONEER 2 (822 adults on metformin): versus empagliflozin 25 mg, HbA1c fell 1.3% versus 0.9% at 26 weeks; superior weight loss was not confirmed at 26 weeks⁶.
• PIONEER 3 (1,864 adults): versus sitagliptin 100 mg, the 7 and 14 mg arms lowered HbA1c 0.3 and 0.5 points more; the 3 mg arm did not show non-inferiority⁷.
• PIONEER 4 (711 adults): non-inferior to subcutaneous liraglutide 1.8 mg for HbA1c (−1.2% versus −1.1%) with more weight loss at 26 weeks (−4.4 kg versus −3.1 kg)⁸.
• PIONEER 8 (added to insulin): HbA1c fell 0.5, 0.9 and 1.2 points more than placebo and weight 0.9, 2.0 and 3.3 kg more⁹.

On cardiovascular safety, PIONEER 6 (3,183 high-risk adults) showed non-inferiority versus placebo: major cardiovascular events in 3.8% versus 4.8% (HR 0.79; 95% CI 0.57–1.11)¹⁰. SOUL (9,650 adults with type 2 diabetes and cardiovascular disease, kidney disease or both, median follow-up 49.5 months) went further: 12.0% versus 13.8% with placebo (HR 0.86; 95% CI 0.77–0.96; P = 0.006)¹¹.

Is Rybelsus used for weight loss? The OASIS trials

In the PIONEER trials weight was a secondary endpoint and differences were modest (2.3 kg more than placebo with 14 mg in PIONEER 1)⁵. The weight indication belongs to a different product: the indications quoted in the Rybelsus label cover glycemic control and cardiovascular risk reduction in type 2 diabetes², and the Wegovy pill at 25 mg is the one the FDA approved for excess weight³.

The OASIS program tested higher doses in people with overweight or obesity:

• OASIS 4 (307 adults without diabetes, 25 mg, 64 weeks): −13.6% of body weight versus −2.2% with placebo (difference −11.4 points; 95% CI −13.9 to −9.0). Gastrointestinal events: 74.0% versus 42.2%¹³. The manufacturer reports 16.6% loss "when treatment was adhered to", a different figure because it excludes people who stopped³.
• OASIS 1 (667 adults, 50 mg, 68 weeks): −15.1% versus −2.4%; 34% reached a loss of at least 20% versus 3%. Gastrointestinal events: 80% versus 46%¹².
• OASIS 2 (201 adults in Japan and South Korea, 50 mg): −14.3% versus −1.3%; 4.5% stopped because of adverse events¹⁴.

Oral vs injectable semaglutide: which works better?

The core question behind "oral vs injectable semaglutide" is whether the pill matches the pen. We found no published trial comparing the 25 mg pill directly with injectable semaglutide 2.4 mg in obesity. What exists are separate placebo-controlled trials: −14.9% at 68 weeks with the injection in STEP 1¹⁵ and −13.6% at 64 weeks with the 25 mg pill in OASIS 4¹³. Populations, duration and methods differ, so the numbers guide but do not prove equivalence. For the rest of the class, see the GLP-1 guide and Wegovy: what semaglutide 2.4 mg is used for.

In type 2 diabetes the pill was compared with other oral and injectable drugs: superior to empagliflozin and sitagliptin for HbA1c and non-inferior to injectable liraglutide⁶⁷⁸. Against orforglipron, a non-peptide oral agonist, ACHIEVE-3 showed a larger HbA1c reduction with orforglipron (−1.71 and −1.91 points versus −1.23 and −1.47 with oral semaglutide 7 and 14 mg), at the cost of more gastrointestinal events; it was an open-label trial funded by its manufacturer¹⁶. The practical difference no trial removes is absorption: the pill depends on stomach conditions, the pen does not²⁴.

Side effects, safety and limits of the evidence

The most common adverse events are gastrointestinal, mainly nausea⁹, and they were more frequent in the high-dose trials: 74.0% with 25 mg in OASIS 4 and 80% with 50 mg in OASIS 1, versus 42.2% and 46% with placebo¹²¹³. The Rybelsus label carries a boxed warning ("WARNING: RISK OF THYROID C-CELL TUMORS"): in rodents, semaglutide causes dose- and treatment-duration-dependent thyroid C-cell tumors².

Two limits are worth stating. First, nearly all the trials cited were funded by Novo Nordisk, and several authors declare ties to the company⁵⁷¹²¹³. Second, not everything that was tried worked: in evoke and evoke+ (3,808 adults with early Alzheimer's disease), oral semaglutide 14 mg did not slow clinical progression (CDR-SB difference −0.08 and 0.10, not significant) and both trials were discontinued¹⁷. Effectiveness in each condition must be read from its own trial.

Frequently asked questions

Are semaglutide pills the same as the injection? Same active ingredient, but a different formulation that includes SNAC and a much higher oral dose, because only 0.4% to 1% is absorbed²⁴.

What is the difference between Rybelsus and the Wegovy pill? Rybelsus is indicated in type 2 diabetes; the Wegovy pill (25 mg) was approved for excess weight and for reducing major cardiovascular events¹²³.

Why must it be taken on an empty stomach? Because absorption happens in the stomach next to the tablet, and food or liquids interfere; the label requires waiting 30 minutes before eating or taking other medicines²⁴.

Is there a difference in weight-loss efficacy? There is no published head-to-head comparison; separate trials show figures of the same size (−13.6% with the 25 mg pill and −14.9% with the 2.4 mg pen)¹³¹⁵. What happens after stopping these drugs is reviewed in GLP-1: muscle, rebound, eyes and pancreas.